Clinical Trials Logo

Clinical Trial Summary

Radiation therapy is a crucial part in the comprehensive treatment of breast cancer. In recent years, emerging systemic treatment regimens such as HER 2 inhibitors, CDK 4/6 inhibitors, PARP inhibitors, capecitabine and PD1 inhibitors have greatly improved the prognosis of breast cancer and has become the standard treatment for specific populations. A considerable number of patients require both radiotherapy and maintenance systemic therapy. However, it is not clear whether systemic therapy should be synchronized or suspended in radiotherapy,despite that previous basic research shows that some molecular drug therapy and radiotherapy has a clear synergy mechanism. There is an agent need for a definite evidence to evaluate the safety of synchronous treatment, to support clinical diagnosis and treatment and the next step of comprehensive treatment. The implementation of the new radiotherapy technology represented by IMRT takes into account the prescription dose homogenization and the minimization of normal tissue dosage, which provides a certain basis for the combination therapy. Based on the above conditions, this study intends to enroll patients between 18 and 70 years old with chest wall / breast ± lymphatic drainage area and requiring capecitabine, CDK 4/ 6 inhibitor, HER2 targeted therapy or immunotherapy. Radiation and novel systemic therapies would be delivered concurrently. The study aimed at evaluating the safety of combined treatments.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06197581
Study type Interventional
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Yirui Zhai, MD
Phone +86-10-87788058
Email januarywind@163.com
Status Recruiting
Phase N/A
Start date September 15, 2023
Completion date September 15, 2026

See also
  Status Clinical Trial Phase
Completed NCT04277650 - System for High-Intensity Evaluation During Radiotherapy N/A
Recruiting NCT05959720 - Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Recruiting NCT06041477 - Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC Phase 3
Recruiting NCT06012253 - The Effect of Home-Based Walking Program on Peripheral Neuropathy, Fatigue and Quality of Life N/A
Recruiting NCT06421610 - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. Phase 1
Not yet recruiting NCT04965532 - Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia N/A
Completed NCT04843410 - Effect of Exercise in the Management of Peripheral Neuropathy N/A
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A
Terminated NCT04607668 - Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): Phase 3
Completed NCT05635929 - Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients. N/A
Recruiting NCT06357871 - Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
Completed NCT02996201 - Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial N/A
Completed NCT00292526 - Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients Phase 4
Completed NCT04663178 - Foot Bath and Chemotherapy Induced Fatigue N/A
Recruiting NCT03191461 - Myocardial Perfusion and Fibrosis in Cancer Survivors
Recruiting NCT05251922 - Tolerance of Anti-Cancer Therapy in the Elderly
Not yet recruiting NCT06387901 - Investigating Paclitaxel Toxicity in Breast Cancer: The Roles of Physical Activity and Body Composition.
Recruiting NCT05892146 - Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction N/A
Not yet recruiting NCT05921149 - Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer N/A
Recruiting NCT05302336 - AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer Phase 4